Regenxbio said its Duchenne muscular dystrophy (DMD) gene therapy reached the necessary bar in a pivotal study, with the company aiming for an FDA submission in 2027. The milestone centers on sufficiently high levels of a key miniaturized muscle protein intended to restore function in DMD patients. The company’s messaging follows recent FDA scrutiny in the gene therapy category and underscores how potency metrics, not just clinical endpoints, are shaping development timelines. Regenxbio positions the result as a path to regulatory review—especially as it competes in an increasingly crowded Duchenne landscape. Market reaction in the broader news flow reflected the fragility of gene therapy development and investor expectations around safety signals and dose-response consistency.